Parnax Lab News
News
0
Ticker
506128.BO
ISIN
INE383L01019
Parnax Lab Eulerpool News
Parnax Lab Stock News
Parnax Lab is being monitored by journalists and investors worldwide. We gather the latest Parnax Lab news here.
Parnax Lab Stock Press Releases
Parnax Lab regularly publishes news on the company's website that are relevant for investors.
Parnax Lab News 2026
This page contains all current news, analysis and press releases for Parnax Lab stock (506128.BO, ISIN: INE383L01019). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Parnax Lab.
Parnax Lab Stock
Parnax Lab Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems.